Immunotherapy used after chemoradiotherapy shows better survival outcomes for patients with cervical cancer.
Using immunotherapy after chemoradiotherapy is safe and effective for patients with cervical cancer, according to study findings published in JAMA Oncology.
For most women with lymph node-positive cervical cancer, the dis- ease recurs despite chemoradiotherapy, according to the researchers, who said they wanted to examine immunotherapy in the upfront treatment setting.
From December 2012 to August 2016, 34 women with stage 1b2 to 4a cervical cancer with positive pelvic lymph nodes, para-aortic lymph nodes or both were enrolled in the clinical trial. Patients were a median age of 50 and most (69%) were white.
Thirteen patients were excluded from analysis because they didn’t receive Yervoy (ipilimumab), a type of immunotherapy. However, 21 women went on to get the medication via IV infusion every 21 days for four doses following chemoradiotherapy.
Researchers saw a survival benefit in the women who received Yervoy. The 12-month overall survival rate was 90%, and 81% of women lived without their disease worsening. Just two patients had grade 3 side effects, dermatitis and an increase in lipase (a protein made by the pancreas).
Extending Healing Commitment to a Cancer Community
April 30th 2024It is Meaghan’s unwavering dedication to supporting children and families during a parent’s illness, along with her willingness to take her direct patient care to practices within her professional position and her community service, that allow me to say Meaghan is truly an extraordinary healer deserving of this honor.
Read More
The Essence of Remarkable Cancer Care
April 29th 2024This year marks the 18th year that CURE and Oncology Nursing News have hosted the Extraordinary Healer Award for Oncology Nursing, which gives people the opportunity to recognize and honor the oncology nurses who have made a significant impact on their life.
Read More
Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
November 30th 2023Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Listen